

For Immediate Release

TSX Exchange Symbol: **RVX**

Resverlogix Announces Research Advances in Ophthalmology

Research presented at 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology

Suite 202

279 Midpark Way SE

Calgary AB T2X 1M2

P 403.254.9252

F 403.256.8495

info@resverlogix.com

Calgary, AB May 9, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce today that the research it sponsors in the laboratory of Dr. M. Francesca Cordeiro, Reader at UCL Institute of Ophthalmology (IoO), University College London and Hon. Consultant Ophthalmologist Western Eye Hospital, London, was presented in a poster during the 2007 Annual Meeting for the Association for Research Vision and Ophthalmology. One of the most interesting findings of this research is that it has demonstrated a successful method and route of delivery for a potential therapeutic to select cells in the back of the eye. These findings will be used for testing and development of Resverlogix’s TGF-Beta Shield™ technology.

Resverlogix, through its sponsored research agreement is focused on the development of a therapeutic approach to modulate the deleterious effects of Transforming Growth Factor-Beta (TGF-Beta) in glaucomatous eyes, as well as in other fibrotic and ophthalmic conditions. The results of this research by Dr. Cordeiro et al have revealed a very precise dose and route of administration for testing the TGF-Beta Shield product.

Donald McCaffrey, President & CEO of Resverlogix, stated, “A key challenge for any therapy that targets the back of the eye is finding a successful delivery method. This finding is one of many important steps to advancing our research towards the successful development of a novel therapeutic to treat fibrotic diseases. Worldwide, Glaucoma is the leading cause of blindness and thus an important area of research for Resverlogix. We are hopeful that this may represent a brand new approach in the treatment of Glaucoma and related diseases.”

The Institute of Ophthalmology together with Moorfields Eye Hospital forms one of the largest single sites for eye care and research in the world. Dr. Cordeiro’s group at the IoO has an international reputation in the field of Glaucoma research, and has been awarded the 2005 Lewis Rudin Prize for the best research paper published worldwide in 2004. The collective knowledge, know-how and expertise at the IoO will aid in the development of the TGF-Beta Shield program.

As of 2003, glaucoma affected 3 million people in the U.S. with 2% being over the age of 40, and 6% over the age of 65. Globally, glaucoma affects 67 million people, 10% of which suffer from bilateral blindness. Glaucoma is characterized by increased intraocular pressure (IOP), progressive optic nerve damage and visual field loss leading to blindness. Recent findings have demonstrated a role for TGF- Beta in the progression of this devastating disease.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company’s primary focus is to conduct leading research, development and commercialization of novel therapeutics that enhance ApoA-I to address atherosclerosis, the main underlying cause of cardiovascular disease (CVD). The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Kenneth Lebioda
SVP, Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Ken@resverlogix.com

Website: www.resverlogix.com